Peking University
pku.edu.cnMatched: Peking University People's Hospital · Peking University · Peking University Cancer Hospital & Institute
Live pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
2,381
Active
775
Phase 3
78
Total enrollment
6,863,071
Pipeline matrix
Showing 40 of 480 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexamethasone | — | — | 16 | ||||
| Esketamine | — | — | — | — | — | 10 | |
| Dexmedetomidine | — | — | — | — | 29 | ||
| Normal saline | — | — | — | — | 14 | ||
| Dexmedetomidine-esketamine combination | — | — | — | — | 6 | ||
| Sirolimus | — | — | 6 | ||||
| Pyrotinib | — | — | — | 4 | |||
| Metformin | — | — | — | — | 5 | ||
| Prednisone | — | — | — | 7 | |||
| Remimazolam | — | — | — | — | — | 4 | |
| Dose escalation | — | — | — | — | 2 | ||
| Combined dexmedetomidine-esketamine administration | — | — | — | — | — | 2 | |
| Dex-Esk | — | — | — | — | — | 2 | |
| Propofol | — | — | — | — | 7 | ||
| Dexmedetomidine-esketamine | — | — | — | — | — | 2 | |
| High-dose anrikefon | — | — | — | — | — | 2 | |
| Medium-dose anrikefon | — | — | — | — | — | 2 | |
| Low-dose anrikefon | — | — | — | — | — | 2 | |
| Cyclosporine | — | — | — | — | — | 2 | |
| methylcobalamin | — | — | — | — | 2 | ||
| Cholecalciferol | — | — | — | — | 2 | ||
| Secukinumab | — | — | — | — | — | 1 | |
| Esketamine-dexmedetomidine combination | — | — | — | — | — | 1 | |
| SURGICEL® Powder | — | — | — | — | — | 1 | |
| OnabotulinumtoxinA | — | — | — | — | — | 1 | |
| Liposomal bupivacaine | — | — | — | — | — | 1 | |
| Plain bupivacaine | — | — | — | — | — | 1 | |
| allogeneic platelet plasma | — | — | — | — | — | 1 | |
| autologous platelet plasma | — | — | — | — | — | 1 | |
| Bivalirudin | — | — | — | — | — | 1 | |
| standard heparin | — | — | — | — | — | 1 | |
| Metronidazole vaginal suppositories | — | — | — | — | — | 1 | |
| Metronidazole vaginal suppositories and Probiotics | — | — | — | — | — | 1 | |
| Liraglutide and metformin | — | — | — | — | — | 1 | |
| Doxorubicin+Ifosfamide+Anlotinib | — | — | — | — | — | 1 | |
| Light anesthesia | — | — | — | — | — | 1 | |
| Deep anesthesia | — | — | — | — | — | 1 | |
| Nanocrystal Megestrol Acetate in Combination with First-Line Standard Immuno-Chemotherapy Regimen | — | — | — | — | — | 1 | |
| First-Line Standard Immuno-Chemotherapy Regimen | — | — | — | — | — | 1 | |
| anti-CD25 rhMAb | — | — | — | — | — | 1 |
440 more active programs hidden
Next readouts
- 2022-06
- 2022-06-30
- 2022-06-30
- 2023-10
- 2023-12-01
- 2023-12-15
- 2023-12-31
- 2023-12-31
- 2023-12-31
- 2024-03-01
Top conditions
- Dexmedetomidine44
- Gastric Cancer42
- Breast Cancer40
- Immune Thrombocytopenia35
- Prostate Cancer26
- Esketamine24
- Lung Cancer21
- Amyotrophic Lateral Sclerosis20
Frequently asked questions about Peking University
- How many clinical trials does Peking University have on ClinicalTrials.gov?
- Peking University is listed as the lead sponsor on 2,381 clinical trials in ClinicalTrials.gov, 775 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Peking University's trials are in Phase 3?
- 78 of Peking University's trials are in Phase 3, spread across 480 active drug programs.
- What therapeutic areas does Peking University focus on?
- Peking University's most-studied conditions on ClinicalTrials.gov are Dexmedetomidine, Gastric Cancer, Breast Cancer, Immune Thrombocytopenia, Prostate Cancer.
- When are Peking University's next clinical trial readouts?
- Peking University has 10 upcoming primary-completion readouts tracked here; the soonest is “Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer”, expected around 2022-06.